drugset / Trial / NCT01355965

Autologous Redirected RNA Meso-CIR T Cells

NCT01355965

Phase 1 Completed 18 enrolled University of Pennsylvania
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To determine the safety and manufacturing feasibility of IV autologous chimeric immune receptor (CIR) T cells transfected with anti-mesothelin messenger RNA (mRNA) expressing a single chain antibody variable fragment linked to the intracellular CD 3 zeta T cell receptor domain and the 4-1BB costimulatory domain.

Timeline

Start
2011-05
Primary completion
2015-07
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject therapeutic autologous lymphocytes Cell therapy 1e+08 cells Intravenous
Subject therapeutic autologous lymphocytes Cell therapy 1e+09 cells Intravenous